Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN – Research Report), United Therapeutics (UTHR – Research Report) and Arcus Biosciences (RCUS – Research Report).
BioMarin Pharmaceutical (BMRN)
In a report released today, Andreas Argyrides from Wedbush reiterated a Hold rating on BioMarin Pharmaceutical, with a price target of $70.00. The company’s shares closed last Wednesday at $88.40.
According to TipRanks.com, Argyrides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $110.00.
United Therapeutics (UTHR)
Wedbush analyst Liana Moussatos reiterated a Buy rating on United Therapeutics today and set a price target of $263.00. The company’s shares closed last Wednesday at $228.52.
According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $256.11, which is a 13.6% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $254.00 price target.
Arcus Biosciences (RCUS)
In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Arcus Biosciences, with a price target of $68.00. The company’s shares closed last Wednesday at $26.35.
According to TipRanks.com, Shu has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $50.83 average price target, representing a 96.0% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $51.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
- Thomson Reuters Reports Second-Quarter 2022 Results
- SUPERIOR GOLD PROVIDES NOTICE OF SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS AND CONFERENCE CALL
- SeaWorld Entertainment, Inc. Reports Second Quarter and First Six Months 2022 Results; Announces New Share Repurchase Program
- New Gold Reports 2022 Second Quarter Results
- Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update